| UniProt/SwissProt ID: | CATD_HUMAN |
| Description: | cathepsin D [Source:HGNC Symbol;Acc:2529] |
| Location: | chr11 p15.5 |
| Node attribute: | gene |
| Phosphorylation site |
| Position | PhosphoPeptide | Catalytic kinase | Source |
|---|---|---|---|
| Y354 | LSPEDyTLKVS | Asp | PhosphoSitePlus |
| Y325 | LIQGEyMIPCE | Asp | PhosphoSitePlus |
| S252 | LGGTDsKYYKG | HPRD | |
| Y347 | LGGKGyKLSPE | Asp | PhosphoSitePlus |
| Dephosphorylation site |
| CATD_HUMAN do not have dephosphorylation site. |
| Mutation site |
| CATD_HUMAN do not have mutation site. |
| Differential expressed protein |
| Ensembl ID | Cancer name | Design | Sample | Change | Ratio | Pubmed |
|---|---|---|---|---|---|---|
| ENSP00000236671 | hepatitis C virus | Normal vs. Cancer | tissue | Down | 0.2 | 18715028 | ENSP00000236671 | Hepatocellular Carcinoma | Normal vs. Cancer | cell line | Up | 7.9 | 18646787 | ENSP00000236671 | Breast Cancer | Metastasis | cell line | Up | 16637015 | ENSP00000236671 | Pancreatic Cancer | Normal vs. Cancer | tissue | Up | 6.7 | 16215274 | ENSP00000236671 | colorectal cancer | Normal vs. Cancer | tissue | Up | 1.7 | 14997500 | ENSP00000236671 | colorectal cancer | Normal vs. Cancer | tissue | Down | 0.71 | 15924290 | ENSP00000236671 | Breast Cancer | Treatment (Antiestrogen-sensitive vs. Antiestrogen-resistant) | cell line | Down | 0.04 | 14557597 | ENSP00000236671 | Breast Cancer | Metastasis | cell line | Up | 16637015 | ENSP00000236671 | Melanoma | Treatment (none vs. metastasis suppressor 1 (BRMS1) overEXPressed) | cell line | Down | 0.35 | 17854218 | ENSP00000236671 | Melanoma | Treatment (none vs. metastasis suppressor 1 (BRMS1) silenced) | cell line | Up | 2.5 | 17854218 | ENSP00000236671 | Breast Cancer | Metastasis | tissue | Down | 18257521 | ENSP00000236671 | hepatitis C virus | Normal vs. Cancer | tissue | Down | 0.19 | 16097030 | ENSP00000236671 | Hepatocellular Carcinoma | Normal vs. Cancer | cell line | Up | 17214954 | ENSP00000236671 | Hepatocellular Carcinoma | Metastasis | cell line | Up | 17214954 | ENSP00000236671 | Hepatocellular Carcinoma | Metastasis | cell line | Up | 17214954 | ENSP00000236671 | hepatitis B virus | Treatment (none vs tetracycline-treatment) | cell line | Up | 2.1 | 19671925 | ENSP00000236671 | Hepatocellular Carcinoma | Cancer vs. Cancer (HCC vs. HuCCA) | cell line | Up | 20069059 | ENSP00000236671 | Colorectal Cancer | Treatment (none vs transfected with HPV-16 E6 gene) | cell line | Up | 15684709 | ENSP00000236671 | Lung Cancer | Cancer vs. Cancer | cell line | Up | 17284061 | ENSP00000236671 | Non-small cell lung carcinoma | Treatment (none vs CIGB-300 treatment) | cell line | Down | 0.3 | 20804217 | ENSP00000236671 | Breast Cancer | Metastasis | cell line | Up | 1.3 | 18582095 | ENSP00000236671 | Breast Cancer | Normal vs. Cancer | tissue | Up | 2 | 20005186 | ENSP00000236671 | Breast Cancer | Normal vs. Cancer | cell line | Up | 5.2 | 20052998 | ENSP00000236671 | Breast Cancer | Normal vs. Cancer | cell line | Up | 7.8 | 20052998 | ENSP00000236671 | Breast Cancer | Normal vs. Cancer | cell line | Up | 8.4 | 20052998 | ENSP00000236671 | Breast Cancer | Normal vs. Cancer | cell line | Up | 9.9 | 20052998 | ENSP00000236671 | Breast Cancer | Normal vs. Cancer | cell line | Down | 0.11 | 20052998 | ENSP00000236671 | Breast Cancer | Normal vs. Cancer | cell line | Down | 0.19 | 20052998 | ENSP00000236671 | Breast Cancer | Normal vs. Cancer | cell line | Down | 0.48 | 20052998 | ENSP00000236671 | Breast Cancer | Normal vs. Cancer | cell line | Down | 0.68 | 20052998 | ENSP00000236671 | Breast Cancer | Metastasis | cell line | Down | 0.011 | 20052998 | ENSP00000236671 | Breast Cancer | Metastasis | cell line | Down | 0.019 | 20052998 | ENSP00000236671 | Breast Cancer | Metastasis | cell line | Down | 0.025 | 20052998 | ENSP00000236671 | Breast Cancer | Metastasis | cell line | Down | 0.056 | 20052998 | ENSP00000236671 | Breast Cancer | Normal vs. Cancer | tissue | Up | 1.8 | 20087651 | ENSP00000236671 | Breast Cancer | Normal vs. Cancer | tissue | Up | 0.46 | 20739354 | ENSP00000236671 | Neoplasms by Histologic Type | Cancer vs. Cancer (subtype) | tissue | Up | 2.1 | 16807943 | ENSP00000236671 | Ovarian Cancer | Treatment (Paclitaxel-sensitive vs. Paclitaxel-resistant) | cell line | Up | 11 | 20858016 | ENSP00000236671 | Pancreatic Cancer | Normal vs. Cancer | tissue | Up | <2 | 15526344 | ENSP00000236671 | Pancreatic Cancer | Normal vs. Cancer | tissue | Up | 3.4 | 16230073 | ENSP00000236671 | Hepatocellular Carcinoma | Normal vs. Cancer | tissue | Up | 2.6 | 19658107 |
| Hyperphosphorylation site |
| CATD_HUMAN do not have hyperphosphorylation site. |
| Direct Interaction Pair |
| Source | Target | Relationship | Resource |
|---|---|---|---|
| SP1_HUMAN | CATD_HUMAN | TF -> target gene | TRANSFAC |
| ESR1_HUMAN | CATD_HUMAN | TF -> target gene | TRANSFAC |
| ESR2_HUMAN | CATD_HUMAN | TF -> target gene | TRANSFAC |
| USF1_HUMAN | CATD_HUMAN | TF -> target gene | TRANSFAC |
| Function Annotation |
| KEGG Pathway |
| CATD_HUMAN is not in KEGG pathway. |
| Gene Ontology |
| GO ID | GO_Term | Evidence | Ontology |
|---|---|---|---|
| GO:0005764 | lysosome | IEA | cellular_component |
| GO:0043202 | lysosomal lumen | TAS | cellular_component |
| GO:0031012 | extracellular matrix | IDA | cellular_component |
| GO:0005615 | extracellular space | IDA | cellular_component |
| GO:0008219 | cell death | IEA | biological_process |
| GO:0000045 | autophagic vacuole assembly | IEA | biological_process |
| GO:0019886 | antigen processing and presentation of exogenous p | TAS | biological_process |
| GO:0005739 | mitochondrion | IEA | cellular_component |
| GO:0005576 | extracellular region | NAS | cellular_component |
| GO:0008233 | peptidase activity | IEA | molecular_function |
| GO:0006508 | proteolysis | IEA | biological_process |
| GO:0042470 | melanosome | IEA | cellular_component |
| GO:0004190 | aspartic-type endopeptidase activity | IEA | molecular_function |